Dynamic Technology Lab Private Ltd Sells 11,224 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Dynamic Technology Lab Private Ltd decreased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 70.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,682 shares of the company's stock after selling 11,224 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Amphastar Pharmaceuticals were worth $227,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the period. Innealta Capital LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $55,000. Blue Trust Inc. grew its stake in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock valued at $70,000 after buying an additional 309 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth $78,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after acquiring an additional 301 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AMPH shares. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price target on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $60.33.

Insider Activity

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at $3,900,522.90. This represents a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO William J. Peters sold 7,426 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,533 shares of company stock worth $1,378,252. Company insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock traded down $0.96 during trading hours on Tuesday, hitting $44.92. The stock had a trading volume of 308,292 shares, compared to its average volume of 454,287. The company has a 50-day moving average of $47.73 and a two-hundred day moving average of $44.60. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The company has a market cap of $2.16 billion, a PE ratio of 14.97, a price-to-earnings-growth ratio of 0.91 and a beta of 0.78.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.